Business Context and Reporting Period
This Form 8-K Current Report was filed by Protagonist Therapeutics, Inc. (PTGX) on January 6, 2025, covering an event that occurred on January 1, 2025. The company is a Delaware corporation with principal executive offices in Newark, California, and its common stock trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event and does not contain financial performance data.
Material Changes
Effective January 1, 2025, Suneel Gupta, Ph.D., transitioned from the role of Chief Development Officer to Executive Vice President, Clinical Development. No other material changes to the company's operations or financial status were reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is limited to the announcement of the officer's title change.
Investor Verification Checklist
- Verify the effective date of Suneel Gupta's title change (January 1, 2025).
- Confirm the new title: Executive Vice President, Clinical Development.
- Review the company's most recent 10-K or 10-Q for financial metrics not included in this 8-K.